Mereo BioPharma Group plc (MAH0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has a cash flow conversion efficiency ratio of -0.188x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.68 Million ≈ $-8.98 Million USD) by net assets (€40.92 Million ≈ $47.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mereo BioPharma Group plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Mereo BioPharma Group plc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Mereo BioPharma Group plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mereo BioPharma Group plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clean TEQ Water Ltd
AU:CNQ
|
-0.130x |
|
Fridenson
TA:FRDN
|
-0.054x |
|
Carbon Streaming Corp
NEO:NETZ
|
0.006x |
|
Logindo Samudramakmur Tbk
JK:LEAD
|
0.069x |
|
Unisync Corp
TO:UNI
|
0.082x |
|
Dcon Products Public Company Limited
BK:DCON
|
0.001x |
|
TDb Split Corp
TO:XTD
|
-0.045x |
|
Beamtree Holdings Ltd
AU:BMT
|
0.011x |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group plc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group plc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Mereo BioPharma Group plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €40.92 Million ≈ $47.84 Million |
€-30.97 Million ≈ $-36.21 Million |
-0.757x | -40.56% |
| 2024-12-31 | €60.97 Million ≈ $71.28 Million |
€-32.83 Million ≈ $-38.39 Million |
-0.539x | -28.79% |
| 2023-12-31 | €50.54 Million ≈ $59.08 Million |
€-21.13 Million ≈ $-24.71 Million |
-0.418x | +33.36% |
| 2022-12-31 | €61.87 Million ≈ $72.33 Million |
€-38.82 Million ≈ $-45.38 Million |
-0.627x | -953.98% |
| 2021-12-31 | €88.00 Million ≈ $102.88 Million |
€-5.24 Million ≈ $-6.12 Million |
-0.060x | -103.14% |
| 2020-12-31 | €-14.97 Million ≈ $-17.50 Million |
€-28.34 Million ≈ $-33.13 Million |
1.893x | +265.92% |
| 2019-12-31 | €40.26 Million ≈ $47.06 Million |
€-45.93 Million ≈ $-53.70 Million |
-1.141x | -61.59% |
| 2018-12-31 | €32.77 Million ≈ $38.31 Million |
€-23.14 Million ≈ $-27.05 Million |
-0.706x | -37.23% |
| 2017-12-31 | €62.48 Million ≈ $73.05 Million |
€-32.15 Million ≈ $-37.59 Million |
-0.515x | -37.48% |
| 2016-12-31 | €79.26 Million ≈ $92.66 Million |
€-29.66 Million ≈ $-34.68 Million |
-0.374x | -- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more